Skip to main content

Advertisement

SpringerLink
Log in

Experimental models and therapeutic approaches for HBV

  • Review
  • Published:
Seminars in Immunopathology Aims and scope Submit manuscript

Abstract

Liver disease associated to persistent infection with the hepatitis B virus (HBV) continues to be a major health problem of global impact. In spite of the existence of an effective vaccine, approximately 360 million people are chronically infected worldwide, who are at high risk of developing liver cirrhosis and hepatocellular carcinoma. Although current therapeutic regimens can efficiently suppress viral replication, the unique replication strategies employed by HBV permit the virus to persist within the infected hepatocytes. As a consequence, relapse of viral activity is commonly observed after cessation of treatment with polymerase inhibitors. The narrow host range of HBV has hindered progresses in understanding specific steps of HBV replication and the development of more effective therapeutic strategies aiming at achieving sustained viral control and, eventually, virus eradication. This review will focus on summarizing recent advances obtained with well-established and more innovative experimental models, giving emphasis on the strength of the different systems as tools for elucidating distinct aspects of HBV persistence and for the development of new therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nassal M, Hepatitis B (2008) Viruses: reverse transcription a different way. Virus Res 134:235–249

    Article  PubMed  CAS  Google Scholar 

  2. Schaefer S, Hepatitis B (2007) Virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 13:14–21

    PubMed  CAS  Google Scholar 

  3. Liaw YF, Brunetto MR, Hadziyannis S (2010) The natural history of chronic HBV infection and geographical differences. Antivir Ther 15(Suppl 3):25–33

    Article  PubMed  Google Scholar 

  4. Fung SK, Lok AS (2004) Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 40:790–792

    PubMed  Google Scholar 

  5. Guirgis BS, Abbas RO, Azzazy HM (2010) Hepatitis B virus genotyping: current methods and clinical implications. Int J Infect Dis 14:e941–e953

    Article  PubMed  CAS  Google Scholar 

  6. Lok AS (2004) Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 127:S303–S309

    Article  PubMed  Google Scholar 

  7. Pollicino T, Saitta C, Raimondo G (2011) Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 32:1122–1132

    Article  PubMed  CAS  Google Scholar 

  8. Chemin I, Zoulim F (2009) Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 286:52–59

    Article  PubMed  CAS  Google Scholar 

  9. EASL (2009) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50:227–242

    Article  Google Scholar 

  10. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M et al (2010) Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 52:454–461

    Article  PubMed  CAS  Google Scholar 

  11. Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y et al (2012) Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 56:1006–1011

    Article  PubMed  CAS  Google Scholar 

  12. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L et al (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334:1422–1427

    Article  PubMed  CAS  Google Scholar 

  13. Urban S, Schulze A, Dandri M, Petersen J (2010) The replication cycle of hepatitis B virus. J Hepatol 52:282–284

    Article  PubMed  Google Scholar 

  14. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ et al (2010) Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51:422–430

    Article  PubMed  CAS  Google Scholar 

  15. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B et al (2006) Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44:675–684

    Article  PubMed  CAS  Google Scholar 

  16. Lutgehetmann M, Volzt T, Quaas A, Zankel M, Fischer C, Dandri M et al (2008) Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 13:57–66

    PubMed  CAS  Google Scholar 

  17. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F et al (2008) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26:335–341

    Article  PubMed  CAS  Google Scholar 

  18. Wedemeyer H (2011) Hepatitis D revival. Liver Int 31(Suppl 1):140–144

    Article  PubMed  Google Scholar 

  19. Du J, Wu Z, Ren S, Wei Y, Gao M, Randolph GJ et al (2010) TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine 28:6273–6281

    Article  PubMed  CAS  Google Scholar 

  20. Sells MA, Chen ML, Acs G (1987) Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 84:1005–1009

    Article  PubMed  CAS  Google Scholar 

  21. Sureau C, Romet-Lemonne JL, Mullins JI, Essex M (1986) Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell 47:37–47

    Article  PubMed  CAS  Google Scholar 

  22. Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593–1608, e1-2

    Article  PubMed  CAS  Google Scholar 

  23. Delaney WET, Isom HC (1998) Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 28:1134–1146

    Article  PubMed  CAS  Google Scholar 

  24. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL et al (1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670–1677

    Article  PubMed  CAS  Google Scholar 

  25. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H (1995) A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 69:5437–5444

    PubMed  CAS  Google Scholar 

  26. Ren S, Nassal M (2001) Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. J Virol 75:1104–1116

    Article  PubMed  CAS  Google Scholar 

  27. Durantel D, Carrouee-Durantel S, Werle-Lapostolle B, Brunelle MN, Pichoud C, Trepo C et al (2004) A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 40:855–864

    PubMed  CAS  Google Scholar 

  28. Warner N, Locarnini S (2008) The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48:88–98

    Article  PubMed  CAS  Google Scholar 

  29. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S et al (1995) The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 69:3350–3357

    PubMed  CAS  Google Scholar 

  30. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M (2009) Control of cccDNA function in hepatitis B virus infection. J Hepatol 51:581–592

    Article  PubMed  CAS  Google Scholar 

  31. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G et al (2006) Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130:823–837

    Article  PubMed  CAS  Google Scholar 

  32. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T et al (2012) IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122:529–537

    Article  PubMed  CAS  Google Scholar 

  33. Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M et al (2009) Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 106:19975–19979

    PubMed  CAS  Google Scholar 

  34. Galle PR, Hagelstein J, Kommerell B, Volkmann M, Schranz P, Zentgraf H (1994) In vitro experimental infection of primary human hepatocytes with hepatitis B virus. Gastroenterology 106:664–673

    PubMed  CAS  Google Scholar 

  35. Gripon P, Diot C, Guguen-Guillouzo C (1993) Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology 192:534–540

    Article  PubMed  CAS  Google Scholar 

  36. Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C et al (1988) Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 62:4136–4143

    PubMed  CAS  Google Scholar 

  37. Schulze-Bergkamen H, Untergasser A, Dax A, Vogel H, Buchler P, Klar E et al (2003) Primary human hepatocytes—a valuable tool for investigation of apoptosis and hepatitis B virus infection. J Hepatol 38:736–744

    Article  PubMed  Google Scholar 

  38. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I et al (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655–15660

    Article  PubMed  CAS  Google Scholar 

  39. Billioud G, Pichoud C, Parent R, Zoulim F (2012) Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. J Hepatol 56:1269–1275

    Article  PubMed  CAS  Google Scholar 

  40. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnolzer M et al (2006) Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 43:750–760

    Article  PubMed  CAS  Google Scholar 

  41. Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C et al (2009) In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 136:168–176, e2

    Article  PubMed  CAS  Google Scholar 

  42. Hantz O, Parent R, Durantel D, Gripon P, Guguen-Guillouzo C, Zoulim F (2009) Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol 90:127–135

    Article  PubMed  CAS  Google Scholar 

  43. Schulze A, Mills K, Weiss TS, Urban S (2012) Hepatocyte polarization is essential for the productive entry of the hepatitis B virus. Hepatology 55:373–383

    Article  PubMed  CAS  Google Scholar 

  44. Summers J (1988) The replication cycle of hepatitis B viruses. Cancer 61:1957–1962

    Article  PubMed  CAS  Google Scholar 

  45. Kock J, Rosler C, Zhang JJ, Blum HE, Nassal M, Thoma C (2010) Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog 6:e1001082

    Article  PubMed  CAS  Google Scholar 

  46. Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, Alibrandi A et al (2011) Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol 85:432–439

    Article  PubMed  CAS  Google Scholar 

  47. Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE et al (2009) Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 50:46–55

    Article  PubMed  CAS  Google Scholar 

  48. Jaeschke H (2003) Are cultured liver cells the right tool to investigate mechanisms of liver disease or hepatotoxicity? Hepatology 38:1053–1055

    Article  PubMed  CAS  Google Scholar 

  49. Dandri M, Volz TK, Lutgehetmann M, Petersen J (2005) Animal models for the study of HBV replication and its variants. J Clin Virol 34(Suppl 1):S54–S62

    Article  PubMed  CAS  Google Scholar 

  50. Mason WS, Aldrich C, Summers J, Taylor JM (1982) Asymmetric replication of duck hepatitis B virus DNA in liver cells: free minus-strand DNA. Proc Natl Acad Sci USA 79:3997–4001

    Article  PubMed  CAS  Google Scholar 

  51. Chen HS, Kaneko S, Girones R, Anderson RW, Hornbuckle WE, Tennant BC et al (1993) The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 67:1218–1226

    PubMed  CAS  Google Scholar 

  52. Zoulim F, Saputelli J, Seeger C (1994) Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 68:2026–2030

    PubMed  CAS  Google Scholar 

  53. Dandri M, Schirmacher P, Rogler CE (1996) Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication. J Virol 70:5246–5254

    PubMed  CAS  Google Scholar 

  54. Summers J, Jilbert AR, Yang W, Aldrich CE, Saputelli J, Litwin S et al (2003) Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci USA 100:11652–11659

    Article  PubMed  CAS  Google Scholar 

  55. Summers J, Mason WS (2004) Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 101:638–640

    Article  PubMed  CAS  Google Scholar 

  56. Mason WS, Jilbert AR, Summers J (2005) Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci USA 102:1139–1144

    Article  PubMed  CAS  Google Scholar 

  57. Baumert TF, Yang C, Schurmann P, Kock J, Ziegler C, Grullich C et al (2005) Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology 41:247–256

    Article  PubMed  CAS  Google Scholar 

  58. von Weizsacker F, Kock J, MacNelly S, Ren S, Blum HE, Nassal M (2004) The tupaia model for the study of hepatitis B virus: direct infection and HBV genome transduction of primary tupaia hepatocytes. Methods Mol Med 96:153–161

    Google Scholar 

  59. Barker LF, Chisari FV, McGrath PP, Dalgard DW, Kirschstein RL, Almeida JD et al (1973) Transmission of type B viral hepatitis to chimpanzees. J Infect Dis 127:648–662

    Article  PubMed  CAS  Google Scholar 

  60. Bertoni R, Sette A, Sidney J, Guidotti LG, Shapiro M, Purcell R et al (1998) Human class I supertypes and CTL repertoires extend to chimpanzees. J Immunol 161:4447–4455

    PubMed  CAS  Google Scholar 

  61. Will H, Cattaneo R, Koch HG, Darai G, Schaller H, Schellekens H et al (1982) Cloned HBV DNA causes hepatitis in chimpanzees. Nature 299:740–742

    Article  PubMed  CAS  Google Scholar 

  62. Berthelot P, Courouce AM, Eyquem A, Feldmann G, Jacob J, Ravisse P et al (1984) Hepatitis B vaccine safety monitoring in the chimpanzee: interpretation of results. J Med Primatol 13:119–133

    PubMed  CAS  Google Scholar 

  63. Ohmura T, Ohmizu A, Sumi A, Ohtani W, Uemura Y, Arimura H et al (1987) Properties of recombinant hepatitis B vaccine. Biochem Biophys Res Commun 149:1172–1178

    Article  PubMed  CAS  Google Scholar 

  64. Fujisawa Y, Kuroda S, Van Eerd PM, Schellekens H, Kakinuma A (1990) Protective efficacy of a novel hepatitis B vaccine consisting of M (pre- S2 + S) protein particles (a third generation vaccine). Vaccine 8:192–198

    Article  PubMed  CAS  Google Scholar 

  65. Ogata N, Cote PJ, Zanetti AR, Miller RH, Shapiro M, Gerin J et al (1999) Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 30:779–786

    Article  PubMed  CAS  Google Scholar 

  66. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307:178–180

    Article  PubMed  CAS  Google Scholar 

  67. Eren R, Ilan E, Nussbaum O, Lubin I, Terkieltaub D, Arazi Y et al (2000) Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 32:588–596

    Article  PubMed  CAS  Google Scholar 

  68. Murray JM, Purcell RH, Wieland SF (2006) The half-life of hepatitis B virions. Hepatology 44:1117–1121

    Article  PubMed  CAS  Google Scholar 

  69. Kamili S, Sozzi V, Thompson G, Campbell K, Walker CM, Locarnini S et al (2009) Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 49:1483–1491

    Article  PubMed  CAS  Google Scholar 

  70. Jung MC, Pape GR (2002) Immunology of hepatitis B infection. Lancet Infect Dis 2:43–50

    Article  PubMed  CAS  Google Scholar 

  71. Chisari FV (1997) Cytotoxic T cells and viral hepatitis. J Clin Invest 99:1472–1477

    Article  PubMed  CAS  Google Scholar 

  72. Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65–91

    Article  PubMed  CAS  Google Scholar 

  73. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH et al (2003) CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77:68–76

    Article  PubMed  CAS  Google Scholar 

  74. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV (2004) Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci USA 101:2129–2134

    Article  PubMed  CAS  Google Scholar 

  75. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH et al (2009) The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 83:9652–9662

    Article  PubMed  CAS  Google Scholar 

  76. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV (1999) Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825–829

    Article  PubMed  CAS  Google Scholar 

  77. Wadman M (2011) Chimp research under scrutiny. Nature 480:424–425

    Article  PubMed  CAS  Google Scholar 

  78. Wadman M (2011) Lab bred chimps despite ban. Nature 479:453–454

    Article  PubMed  CAS  Google Scholar 

  79. Jilbert AR, Miller DS, Scougall CA, Turnbull H, Burrell CJ (1996) Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Virology 226:338–345

    Article  PubMed  CAS  Google Scholar 

  80. Delmas J, Schorr O, Jamard C, Gibbs C, Trepo C, Hantz O et al (2002) Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 46:425–433

    Article  PubMed  CAS  Google Scholar 

  81. Addison WR, Walters KA, Wong WW, Wilson JS, Madej D, Jewell LD et al (2002) Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 76:6356–6363

    Article  PubMed  CAS  Google Scholar 

  82. Colledge D, Civitico G, Locarnini S, Shaw T (2000) In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir [In Process Citation]. Antimicrob Agents Chemother 44:551–560

    Article  PubMed  CAS  Google Scholar 

  83. Seigneres B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L et al (2003) Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 47:1842–1852

    Article  PubMed  CAS  Google Scholar 

  84. Foster WK, Miller DS, Scougall CA, Kotlarski I, Colonno RJ, Jilbert AR (2005) Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection. J Virol 79:5819–5832

    Article  PubMed  CAS  Google Scholar 

  85. Caselmann WH (1994) HBV and HDV replication in experimental models: effect of interferon. Antiviral Res 24:121–129

    Article  PubMed  CAS  Google Scholar 

  86. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS (1997) Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 71:9392–9399

    PubMed  CAS  Google Scholar 

  87. Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH et al (1998) Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28:179–191

    Article  PubMed  CAS  Google Scholar 

  88. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS et al (1998) Lamivudine therapy of WHV-infected woodchucks. Virology 245:18–32

    Article  PubMed  CAS  Google Scholar 

  89. Block TM, Lu X, Mehta AS, Blumberg BS, Tennant B, Ebling M et al (1998) Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 4:610–614

    Article  PubMed  CAS  Google Scholar 

  90. Dandri M, Burda MR, Will H, Petersen J (2000) Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 32:139–146

    Article  PubMed  CAS  Google Scholar 

  91. Korba BE, Cote PJ, Menne S, Toshkov I, Baldwin BH, Wells FV et al (2004) Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther 9:937–952

    PubMed  CAS  Google Scholar 

  92. Menne S, Cote PJ, Korba BE, Butler SD, George AL, Tochkov IA et al (2005) Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 49:2720–2728

    Article  PubMed  CAS  Google Scholar 

  93. Lu M, Roggendorf M (2001) Evaluation of new approaches to prophylactic and therapeutic vaccinations against hepatitis B viruses in the woodchuck model. Intervirology 44:124–131

    Article  PubMed  CAS  Google Scholar 

  94. Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE et al (2004) Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 127:S283–S293

    Article  PubMed  Google Scholar 

  95. Cullen JM, Smith SL, Davis MG, Dunn SE, Botteron C, Cecchi A et al (1997) In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 41:2076–2082

    PubMed  CAS  Google Scholar 

  96. Cullen JM, Li DH, Brown C, Eisenberg EJ, Cundy KC, Wolfe J et al (2001) Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 45:2740–2745

    Article  PubMed  CAS  Google Scholar 

  97. Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S et al (1998) Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 42:3209–3217

    PubMed  CAS  Google Scholar 

  98. Jacob JR, Korba BE, Cote PJ, Toshkov I, Delaney WET, Gerin JL et al (2004) Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res 63:115–121

    Article  PubMed  CAS  Google Scholar 

  99. Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML et al (2001) Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 184:1236–1245

    Article  PubMed  CAS  Google Scholar 

  100. Crettaz J, Otano I, Ochoa-Callejero L, Benito A, Paneda A, Aurrekoetxea I et al (2009) Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. J Virol 83:2663–2674

    Article  PubMed  CAS  Google Scholar 

  101. Otano I, Suarez L, Dotor J, Gonzalez-Aparicio M, Crettaz J, Olague C et al (2012) Modulation of regulatory T cell activity in combination with IL-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology 56:474–483

    Article  PubMed  CAS  Google Scholar 

  102. Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, Chi H et al (2008) Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol 82:2598–2603

    Article  PubMed  CAS  Google Scholar 

  103. Lanford RE, Chavez D, Brasky KM, Burns RB 3rd, Rico-Hesse R (1998) Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci USA 95:5757–5761

    Article  PubMed  CAS  Google Scholar 

  104. Walter E, Keist R, Niederost B, Pult I, Blum HE (1996) Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 24:1–5

    PubMed  CAS  Google Scholar 

  105. Yan RQ, Su JJ, Huang DR, Gan YC, Yang C, Huang GH (1996) Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus. J Cancer Res Clin Oncol 122:283–288

    Article  PubMed  CAS  Google Scholar 

  106. Kock J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsacker F (2001) Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 75:5084–5089

    Article  PubMed  CAS  Google Scholar 

  107. Dandri M, Burda MR, Zuckerman DM, Wursthorn K, Matschl U, Pollok JM et al (2005) Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol 42:54–60

    Article  PubMed  CAS  Google Scholar 

  108. Kock J, Baumert TF, Delaney WET, Blum HE, von Weizsacker F (2003) Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology 38:1410–1418

    PubMed  CAS  Google Scholar 

  109. Guidotti LG, Matzke B, Schaller H, Chisari FV (1995) High-level hepatitis B virus replication in transgenic mice. J Virol 69:6158–6169

    PubMed  CAS  Google Scholar 

  110. Guidotti LG, Chisari FV (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1:23–61

    Article  PubMed  CAS  Google Scholar 

  111. Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, Palmiter RD et al (1990) Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 248:361–364

    Article  PubMed  CAS  Google Scholar 

  112. Guidotti LG, Guilhot S, Chisari FV (1994) Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J Virol 68:1265–1270

    PubMed  CAS  Google Scholar 

  113. Guidotti LG, Matzke B, Pasquinelli C, Schoenberger JM, Rogler CE, Chisari FV (1996) The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol 70:7056–7061

    PubMed  CAS  Google Scholar 

  114. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25–36

    Article  PubMed  CAS  Google Scholar 

  115. Heise T, Guidotti LG, Cavanaugh VJ, Chisari FV (1999) Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J Virol 73:474–481

    PubMed  CAS  Google Scholar 

  116. Sitia G, Isogawa M, Iannacone M, Campbell IL, Chisari FV, Guidotti LG (2004) MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 113:1158–1167

    PubMed  CAS  Google Scholar 

  117. McClary H, Koch R, Chisari FV, Guidotti LG (2000) Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 74:2255–2264

    Article  PubMed  CAS  Google Scholar 

  118. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV (2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192:921–930

    Article  PubMed  CAS  Google Scholar 

  119. Pasquetto V, Guidotti LG, Kakimi K, Tsuji M, Chisari FV (2000) Host-virus interactions during malaria infection in hepatitis B virus transgenic mice. J Exp Med 192:529–536

    Article  PubMed  CAS  Google Scholar 

  120. Wieland SF, Vega RG, Muller R, Evans CF, Hilbush B, Guidotti LG et al (2003) Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 77:1227–1236

    Article  PubMed  CAS  Google Scholar 

  121. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV (2002) Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 76:10702–10707

    Article  PubMed  CAS  Google Scholar 

  122. Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV et al (2001) Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 194:1755–1766

    Article  PubMed  CAS  Google Scholar 

  123. Weber O, Schlemmer KH, Hartmann E, Hagelschuer I, Paessens A, Graef E et al (2002) Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res 54:69–78

    Article  PubMed  CAS  Google Scholar 

  124. Julander JG, Colonno RJ, Sidwell RW, Morrey JD (2003) Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Antiviral Res 59:155–161

    Article  PubMed  CAS  Google Scholar 

  125. Julander JG, Sidwell RW, Morrey JD (2002) Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res 55:27–40

    Article  PubMed  CAS  Google Scholar 

  126. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H et al (2003) Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 21:639–644

    Article  PubMed  CAS  Google Scholar 

  127. Klein C, Bock CT, Wedemeyer H, Wustefeld T, Locarnini S, Dienes HP et al (2003) Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 125:9–18

    Article  PubMed  CAS  Google Scholar 

  128. Ebert G, Poeck H, Lucifora J, Baschuk N, Esser K, Esposito I et al (2011) 5′ Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology 141(696–706):e1–e3

    PubMed  Google Scholar 

  129. Sprinzl MF, Oberwinkler H, Schaller H, Protzer U (2001) Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. J Virol 75:5108–5118

    Article  PubMed  CAS  Google Scholar 

  130. Isogawa M, Kakimi K, Kamamoto H, Protzer U, Chisari FV (2005) Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology 333:293–300

    Article  PubMed  CAS  Google Scholar 

  131. Feitelson MA, DeTolla LJ, Zhou XD (1988) A chronic carrierlike state is established in nude mice injected with cloned hepatitis B virus DNA. J Virol 62:1408–1415

    PubMed  CAS  Google Scholar 

  132. Yang PL, Althage A, Chung J, Chisari FV (2002) Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 99:13825–13830

    Article  PubMed  CAS  Google Scholar 

  133. Huang LR, Wu HL, Chen PJ, Chen DS (2006) An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA 103:17862–17867

    Article  PubMed  CAS  Google Scholar 

  134. Lin YJ, Huang LR, Yang HC, Tzeng HT, Hsu PN, Wu HL et al (2010) Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc Natl Acad Sci USA 107:9340–9345

    Article  PubMed  CAS  Google Scholar 

  135. Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, Eren R et al (1999) The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 29:553–562

    Article  PubMed  CAS  Google Scholar 

  136. Bocher WO, Galun E, Marcus H, Daudi N, Terkieltaub D, Shouval D et al (2000) Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse [In Process Citation]. Hepatology 31:480–487

    Article  PubMed  CAS  Google Scholar 

  137. Rhim JA, Sandgren EP, Degen JL, Palmiter RD, Brinster RL (1994) Replacement of diseased mouse liver by hepatic cell transplantation. Science 263:1149–1152

    Article  PubMed  CAS  Google Scholar 

  138. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E et al (2007) Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 25:903–910

    Article  PubMed  CAS  Google Scholar 

  139. Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV et al (2010) Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 120:924–930

    Article  PubMed  CAS  Google Scholar 

  140. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL (1991) Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 66:245–256

    Article  PubMed  CAS  Google Scholar 

  141. Rhim JA, Sandgren EP, Palmiter RD, Brinster RL (1995) Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl Acad Sci USA 92:4942–4946

    Article  PubMed  CAS  Google Scholar 

  142. Petersen J, Dandri M, Gupta S, Rogler CE (1998) Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci USA 95:310–315

    Article  PubMed  CAS  Google Scholar 

  143. Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G et al (2001) Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33:981–988

    Article  PubMed  CAS  Google Scholar 

  144. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A et al (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7:927–933

    Article  PubMed  CAS  Google Scholar 

  145. Meuleman P, Leroux-Roels G (2008) The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res 80:231–238

    Article  PubMed  CAS  Google Scholar 

  146. Dandri M, Petersen J (2012) Chimeric mouse model of hepatitis B virus infection. J Hepatol 56:493–495

    Article  PubMed  Google Scholar 

  147. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J et al (2005) Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41:847–856

    Article  PubMed  CAS  Google Scholar 

  148. Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, Imamura M et al (2005) Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42:1046–1054

    Article  PubMed  CAS  Google Scholar 

  149. Tsuge M, Takahashi S, Hiraga N, Fujimoto Y, Zhang Y, Mitsui F et al (2011) Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice. J Infect Dis 204:224–228

    Article  PubMed  CAS  Google Scholar 

  150. Vanwolleghem T, Libbrecht L, Hansen BE, Desombere I, Roskams T, Meuleman P et al (2010) Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol 53:468–476

    Article  PubMed  Google Scholar 

  151. Dandri M, Burda MR, Gocht A, Torok E, Pollok JM, Rogler CE et al (2001) Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation. Hepatology 34:824–833

    Article  PubMed  CAS  Google Scholar 

  152. Lutgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM et al (2011) Hepatitis B Virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 140:2074–2083

    Article  PubMed  CAS  Google Scholar 

  153. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C et al (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–912

    Article  PubMed  CAS  Google Scholar 

  154. Lutgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T et al (2012) Human chimeric uPA mouse model to study hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55:685–694

    Article  PubMed  CAS  Google Scholar 

  155. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK et al (2006) Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 44:915–924

    Article  PubMed  CAS  Google Scholar 

  156. Tanaka Y, Sanchez LV, Sugiyama M, Sakamoto T, Kurbanov F, Tatematsu K et al (2008) Characteristics of hepatitis B virus genotype G coinfected with genotype H in chimeric mice carrying human hepatocytes. Virology 376:408–415

    Article  PubMed  CAS  Google Scholar 

  157. Tsuge M, Hiraga N, Akiyama R, Tanaka S, Matsushita M, Mitsui F et al (2010) HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. J Gen Virol 91:1854–1864

    Article  PubMed  CAS  Google Scholar 

  158. Hiraga N, Imamura M, Hatakeyama T, Kitamura S, Mitsui F, Tanaka S et al (2009) Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J Hepatol 51:1046–1054

    Article  PubMed  CAS  Google Scholar 

  159. Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M et al (2006) Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 50:3867–3874

    Article  PubMed  CAS  Google Scholar 

  160. Lutgehetmann M, Volz T, Kopke A, Broja T, Tigges E, Lohse AW et al (2010) In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 52:16–24

    Article  PubMed  CAS  Google Scholar 

  161. Okazaki A, Hiraga N, Imamura M, Nelson Hayes C, Tsuge M, Takahashi S et al (2012) Severe necroinflammatory reaction caused by natural killer by Fas/FasL interaction and dendritic cells in human hepatocyte chimeric mouse. Hepatology 56:555–566

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Maura Dandri

  2. Department of Internal Medicine, Department of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Marc Lütgehetmann

  3. IFI Institute for Interdisciplinary Medicine, Asklepios Clinic St. Georg, Hamburg, Germany

    Jörg Petersen

Authors
  1. Maura Dandri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Lütgehetmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jörg Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maura Dandri.

Additional information

This article is published as part of the Special Issue on Immunopathology of viral hepatitis [34:4]

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dandri, M., Lütgehetmann, M. & Petersen, J. Experimental models and therapeutic approaches for HBV. Semin Immunopathol 35, 7–21 (2013). https://doi.org/10.1007/s00281-012-0335-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-012-0335-7

Keywords

Search

Navigation